Andrew McDonald, MD
Radiation Oncology · Birmingham, ALNPI 1114286556
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 45.3% of the total. Reporting peaked in 2023 at $3,736 and has fallen 98.5% since, to $56 in 2025. Among radiation oncology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $127.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$4K
- Varian Medical Systems, Inc.$3K
- Collegium Pharmaceutical, Inc.$299
- Dendreon Pharmaceuticals LLC$131
- Novartis$108
- Bayer$85
- plus $366 from 12 others
Across 10 payments — averaging $24,801 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$181K
- Eli Lilly$30K
- Varian Medical Systems, Inc.$27K
- Medivation LLC.$9K
What the payments were for
- Consulting fees$2,54032%
- Speaking & faculty fees$2,00025%
- Travel & lodging$1,67721%
- Food & beverage$1,69421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 15 | $3,585 |
| Varian Medical Systems, Inc. | 9 | $3,337 |
| Collegium Pharmaceutical, Inc. | 6 | $299 |
| Dendreon Pharmaceuticals LLC | 4 | $131 |
| Novartis | 5 | $108 |
| Bayer | 4 | $85 |
| Pfizer | 3 | $60 |
| Merck | 3 | $58 |
| Sun Pharmaceutical Industries Inc. | 2 | $51 |
| Eisai Inc. | 3 | $46 |
| AstraZeneca | 1 | $24 |
| Telix Pharmaceuticals | 1 | $24 |
| Gilead | 1 | $23 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Isoray, Inc | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Other$2,540
- Varian Ethos Treatment Planning$958
- Radiation Oncology$315
- Halcyon$208
- ProBeam$126
How this compares
$7,910 in reported general payments places this provider in the 90th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 165 | $422,937 |
| Abiraterone Acetate | 48 | $96,869 |
| Tamsulosin Hcl | 212 | $2,274 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $159 |
| Prednisone | 56 | $158 |
| Methylprednisolone | 11 | $119 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $14 |
| Diazepam | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $17 | $422,937165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 87 radiation oncology providers in Alabama.
Other radiation oncology in Birmingham
- Drexell BoggsBirmingham$35K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William EnnisBirmingham$6K
- John StahlBirmingham$3K
- Omer BurnettBirmingham$2K
- Samuel MarcromBirmingham$2K
- Rojymon JacobBirmingham$1K
- Mehran YusufBirmingham$1K
- Ruby MeredithBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.